BML-284 (Wnt Agonist) is a potent and cell-permeable activator of Wnt signaling that induces TCF-dependent transcriptional activity with an EC50 value of 0.7 µM. BML-284 also acts as an agonist of β-catenin that effectively activates direct Wnt-β-catenin signaling to induce adipocyte dedifferentiation while circumventing the apoptotic effect in the hypertonic treatment.

BML-284 (Wnt Agonist) is a potent and cell-permeable activator of Wnt signaling that induces TCF-dependent transcriptional activity with an EC50 value of 0.7 µM. BML-284 also acts as an agonist of β-catenin that effectively activates direct Wnt-β-catenin signaling to induce adipocyte dedifferentiation while circumventing the apoptotic effect in the hypertonic treatment.

BML-284 (Wnt Agonist) is a potent and cell-permeable activator of Wnt signaling that induces TCF-dependent transcriptional activity with an EC50 value of 0.7 µM. BML-284 also acts as an agonist of β-catenin that effectively activates direct Wnt-β-catenin signaling to induce adipocyte dedifferentiation while circumventing the apoptotic effect in the hypertonic treatment.

BIX-01294 is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC50s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 has antitumor activity in recurrent […]

SRI-011381 hydrochloride is an agonist of the transforming growth factor-beta (TGF-β) signalling pathway and exhibits neuroprotective effects with the potential to treat Alzheimer’s disease. It also increases fibronectin expression in the NIH‐3T3 cells stimulated by metformin.

SRI-011381 hydrochloride is an agonist of the transforming growth factor-beta (TGF-β) signalling pathway and exhibits neuroprotective effects with the potential to treat Alzheimer’s disease. It also increases fibronectin expression in the NIH‐3T3 cells stimulated by metformin.

SRI-011381 hydrochloride is an agonist of the transforming growth factor-beta (TGF-β) signalling pathway and exhibits neuroprotective effects with the potential to treat Alzheimer’s disease. It also increases fibronectin expression in the NIH‐3T3 cells stimulated by metformin.

SRI-011381 hydrochloride is an agonist of the transforming growth factor-beta (TGF-β) signalling pathway and exhibits neuroprotective effects with the potential to treat Alzheimer’s disease. It also increases fibronectin expression in the NIH‐3T3 cells stimulated by metformin.

Bobcat339 is a cytosine-based small molecule inhibitor of TET enzyme with IC50 of 33 μM and 73 μM for TET1 and TET2, respectively, reducing DNA 5hmC levels in hippocampal neurons. It is useful in epigenetics research and a potential starting point for therapeutics targeting DNA methylation and gene transcription.

SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.